In this video interview, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced Clinical, discuss ...

This year’s conference highlighted a number of critical areas in clinical R&D including financial management, representation, ...

At the current rate of progress, it will take until 2158 to reach full gender parity based on a global measure of opportunity ...

Genomics has long been a primary focus in precision medicine, but other areas of research are increasingly being used to help ...

In this video interview, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced Clinical, ...

Teams must work together with technology solutions and optimize integration to unlock their full potential. Clinical trials ...

In this video interview, Iddo Peleg, CEO and co-founder at Yonalink, talks innovation in clinical technology and how the FDA can continue to promote its adoption.

Phase III MATTERHORN trial data show a statistically significant and clinically meaningful improvement in event-free survival for patients with resectable gastric and gastroesophageal junction cancer ...

Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...

Phase III REMIX-1 and REMIX-2 trials demonstrated that remibrutinib, an oral BTK inhibitor, significantly reduced chronic ...